Skip to content
Our Top 15 Most-Clicked Stories of 2022
Thanks for joining us in Year 1 of Bio.News. We published over 700 stories in less than one year – and these were the […]
Our Top 15 Most-Clicked Stories of 2022 Read More »
Editors’ Choice
BIO hosts industry and government leaders in Africa Summit side event targeting cancer
The Biotechnology Innovation Organization (BIO) hosted leaders from industry and governments in the U.S. and Africa in an effort to build collaboration against cancer
BIO hosts industry and government leaders in Africa Summit side event targeting cancer Read More »
2022 midterms recap: what happened and what the results mean for biotech
The 2022 midterms are officially behind us – so, what happened, and what does biotech need to know going into the new year? We
2022 midterms recap: what happened and what the results mean for biotech Read More »
How Dobbs v. Jackson is affecting vaccine innovation
Dobbs v. Jackson has had a ripple effect across healthcare—from increasing the danger of medical management of miscarriages and risk of maternal mortality, to
How Dobbs v. Jackson is affecting vaccine innovation Read More »
COVID-19 forced us to reimagine the pharma supply chain – and that’s a good thing
“The pandemic has exposed our country’s dependence on other countries for essential prescription drugs,” began Steve Scully, contributing editor at The Hill and moderator
COVID-19 forced us to reimagine the pharma supply chain – and that’s a good thing Read More »
55% of FDA-approved drugs were developed by U.S. small biotechs, says study
The U.S. was solely responsible for 61% of medicines approved by the U.S. Food and Drug Administration (FDA) between 2011-2020, says a new report
55% of FDA-approved drugs were developed by U.S. small biotechs, says study Read More »
Fight the ‘tripledemic’ with vaccines, tests, and treatment
This is a tough winter for respiratory disease. Coming off of a two-year pandemic we are finding that flu season now has a few
Fight the ‘tripledemic’ with vaccines, tests, and treatment Read More »
To ensure access for all, healthcare payment models need innovation
Paying for healthcare in the United States has been a challenging and controversial issue for years. In a landscape managed by private insurers, Medicaid,
To ensure access for all, healthcare payment models need innovation Read More »
CMS must flesh out plan to ease out-of-pocket drug costs, report says
Provisions in the Inflation Reduction Act (IRA) make it easier for people covered by Medicare Part D to pay for medicine, but continued government
CMS must flesh out plan to ease out-of-pocket drug costs, report says Read More »
Meet Rachel King, BIO’s new interim CEO and a champion of the biotech industry
Rachel King was enjoying her retirement. When the COVID-19 pandemic hit, King found herself with a chance to refocus and ask herself what was
Meet Rachel King, BIO’s new interim CEO and a champion of the biotech industry Read More »